Labcorp Holdings annual shares outstanding
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Labcorp Holdings Shares Outstanding History (LH)
Labcorp Holdings reported 82.2M shares outstanding at the end of fiscal 2025.
View full Labcorp Holdings company overviewLabcorp Holdings annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 82.2M | −1.2M | −1.44% |
| 2024 | 2024-12-31 | 83.4M | −500,000 | −0.60% |
| 2023 | 2023-12-31 | 83.9M | −4.3M | −4.88% |
| 2022 | 2022-12-31 | 88.2M | −4.9M | −5.26% |
| 2021 | 2021-12-31 | 93.1M | −4.4M | −4.51% |
| 2020 | 2020-12-31 | 97.5M | 300,000 | +0.31% |
| 2019 | 2019-12-31 | 97.2M | −1.7M | −1.72% |
| 2018 | 2018-12-31 | 98.9M | −3.0M | −2.94% |
| 2017 | 2017-12-31 | 101.9M | −800,000 | −0.78% |
| 2016 | 2016-12-31 | 102.7M | 1.4M | +1.38% |
| 2015 | 2015-12-31 | 101.3M | 16.7M | +19.74% |
| 2014 | 2014-12-31 | 84.6M | −1.1M | −1.28% |
| 2013 | 2013-12-31 | 85.7M | −7.8M | −8.34% |
| 2012 | 2012-12-31 | 93.5M | −4.3M | −4.40% |
| 2011 | 2011-12-31 | 97.8M | −4.6M | −4.49% |
| 2010 | 2010-12-31 | 102.4M | −2.9M | −2.75% |
| 2009 | 2009-12-31 | 105.3M | −2.9M | −2.68% |
| 2008 | 2008-12-31 | 108.2M | — | — |
Labcorp Holdings quarterly shares outstanding
Q4.08
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 80.9M | −2.0M | −2.41% |
| Q1 2026 | 2026-03-31 | 82.3M | −1.5M | −1.79% |
| Q4 2025 | 2025-12-31 | 82.2M | −1.2M | −1.44% |
| Q3 2025 | 2025-09-30 | 83.0M | −700,000 | −0.84% |
| Q2 2025 | 2025-06-30 | 82.9M | −900,000 | −1.07% |
| Q1 2025 | 2025-03-31 | 83.8M | −500,000 | −0.59% |
| Q4 2024 | 2024-12-31 | 83.4M | −500,000 | −0.60% |
| Q3 2024 | 2024-09-30 | 83.7M | −1.2M | −1.41% |
| Q2 2024 | 2024-06-30 | 83.8M | −4.9M | −5.52% |
| Q1 2024 | 2024-03-31 | 84.3M | −4.3M | −4.85% |
| Q4 2023 | 2023-12-31 | 83.9M | −4.3M | −4.88% |
| Q3 2023 | 2023-09-30 | 84.9M | −4.7M | −5.25% |
| Q2 2023 | 2023-06-30 | 88.7M | −2.3M | −2.53% |
| Q1 2023 | 2023-03-31 | 88.6M | −7.2M | −7.52% |
| Q4 2022 | 2022-12-31 | 88.2M | −4.9M | −5.26% |
| Q3 2022 | 2022-09-30 | 89.6M | −6.2M | −6.47% |
| Q2 2022 | 2022-06-30 | 91.0M | −5.7M | −5.89% |
| Q1 2022 | 2022-03-31 | 95.8M | −2.0M | −2.04% |
| Q4 2021 | 2021-12-31 | 93.1M | −4.4M | −4.51% |
| Q3 2021 | 2021-09-30 | 95.8M | −1.6M | −1.64% |
| Q2 2021 | 2021-06-30 | 96.7M | −600,000 | −0.62% |
| Q1 2021 | 2021-03-31 | 97.8M | 700,000 | +0.72% |
| Q4 2020 | 2020-12-31 | 97.5M | 300,000 | +0.31% |
| Q3 2020 | 2020-09-30 | 97.4M | 0 | 0.00% |
| Q2 2020 | 2020-06-30 | 97.3M | −500,000 | −0.51% |
| Q1 2020 | 2020-03-31 | 97.1M | −1.6M | −1.62% |
| Q4 2019 | 2019-12-31 | 97.2M | −1.7M | −1.72% |
| Q3 2019 | 2019-09-30 | 97.4M | −4.0M | −3.94% |
| Q2 2019 | 2019-06-30 | 97.8M | −4.2M | −4.12% |
| Q1 2019 | 2019-03-31 | 98.7M | −3.4M | −3.33% |
| Q4 2018 | 2018-12-31 | 98.9M | −3.0M | −2.94% |
| Q3 2018 | 2018-09-30 | 101.4M | −700,000 | −0.69% |
| Q2 2018 | 2018-06-30 | 102.0M | 0 | 0.00% |
| Q1 2018 | 2018-03-31 | 102.1M | −500,000 | −0.49% |
| Q4 2017 | 2017-12-31 | 101.9M | −800,000 | −0.78% |
| Q3 2017 | 2017-09-30 | 102.1M | −700,000 | −0.68% |
| Q2 2017 | 2017-06-30 | 102.0M | −200,000 | −0.20% |
| Q1 2017 | 2017-03-31 | 102.6M | 500,000 | +0.49% |
| Q4 2016 | 2016-12-31 | 102.7M | 1.4M | +1.38% |
| Q3 2016 | 2016-09-30 | 102.8M | 1.6M | +1.58% |
| Q2 2016 | 2016-06-30 | 102.2M | 1.4M | +1.39% |
| Q1 2016 | 2016-03-31 | 102.1M | 1.6M | +1.59% |
| Q4 2015 | 2015-12-31 | 101.3M | 16.7M | +19.74% |
| Q3 2015 | 2015-09-30 | 101.2M | 16.3M | +19.20% |
| Q2 2015 | 2015-06-30 | 100.8M | 15.9M | +18.73% |
| Q1 2015 | 2015-03-31 | 100.5M | 15.7M | +18.51% |
| Q4 2014 | 2014-12-31 | 84.6M | −1.1M | −1.28% |
| Q3 2014 | 2014-09-30 | 84.9M | −2.9M | −3.30% |
| Q2 2014 | 2014-06-30 | 84.9M | −5.6M | −6.19% |
| Q1 2014 | 2014-03-31 | 84.8M | −8.0M | −8.62% |
| Q4 2013 | 2013-12-31 | 85.7M | −7.8M | −8.34% |
| Q3 2013 | 2013-09-30 | 87.8M | −7.1M | −7.48% |
| Q2 2013 | 2013-06-30 | 90.5M | −5.3M | −5.53% |
| Q1 2013 | 2013-03-31 | 92.8M | −4.3M | −4.43% |
| Q4 2012 | 2012-12-31 | 93.5M | −4.3M | −4.40% |
| Q3 2012 | 2012-09-30 | 94.9M | −4.8M | −4.81% |
| Q2 2012 | 2012-06-30 | 95.8M | −5.6M | −5.52% |
| Q1 2012 | 2012-03-31 | 97.1M | −3.1M | −3.09% |
| Q4 2011 | 2011-12-31 | 97.8M | −4.6M | −4.49% |
| Q3 2011 | 2011-09-30 | 99.7M | −2.0M | −1.97% |
| Q2 2011 | 2011-06-30 | 101.4M | −1.7M | −1.65% |
| Q1 2011 | 2011-03-31 | 100.2M | −4.0M | −3.84% |
| Q4 2010 | 2010-12-31 | 102.4M | −2.9M | −2.75% |
| Q3 2010 | 2010-09-30 | 101.7M | −4.8M | −4.51% |
| Q2 2010 | 2010-06-30 | 103.1M | −5.7M | −5.24% |
| Q1 2010 | 2010-03-31 | 104.2M | — | — |
| Q4 2009 | 2009-12-31 | 105.3M | −2.9M | −2.68% |
| Q3 2009 | 2009-09-30 | 106.5M | — | — |
| Q2 2009 | 2009-06-30 | 108.8M | — | — |
| Q4 2008 | 2008-12-31 | 108.2M | — | — |
Labcorp Holdings Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. Labcorp Holdings share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
Labcorp Holdings used $450.0M to repurchase common stock in fy 2025. Across the latest 5 reported fiscal years, total share repurchases were $4.47B. The latest reported quarter showed $353.8M of share repurchases.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2025 | 2025-12-31 | $450.0M |
| 2024 | 2024-12-31 | $250.1M |
| 2023 | 2023-12-31 | $1.00B |
| 2022 | 2022-12-31 | $1.10B |
| 2021 | 2021-12-31 | $1.67B |
| 2020 | 2020-12-31 | $100.0M |
| 2019 | 2019-12-31 | $450.0M |
| 2018 | 2018-12-31 | $700.0M |
| 2017 | 2017-12-31 | $338.1M |
| 2016 | 2016-12-31 | $43.9M |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
Labcorp Holdings shares outstanding trends
Over the last five fiscal years, Labcorp Holdings's shares outstanding moved from 97.5M to 82.2M, a change of −15.3M. The latest reported quarter, Q2 2026, shows 80.9M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Labcorp Holdings source filings ↗Community posts
Labcorp sets new medium-term growth targets and reaffirms its annual outlook
Labcorp ($LH) set medium-term targets for annual revenue growth of 5–8% and adjusted earnings-per-share growth of 8.5–11.5% through 2029. The company also reaffirmed its existing 2026 guidance. The new framework describes the performance ma ...
Labcorp acquires MLM Medical Labs to expand clinical-trial services
Labcorp ($LH) acquired MLM Medical Labs, adding central and specialty laboratory operations in the United States, Germany and South Africa. The company said the purchase expands its biomarker-testing capabilities and improves its ability to ...
